Openbookopenbook
Openbook
BIOT
+0.41 · +3.16%
£13.55 · LSE
L&G PHARMA BREAKTHROUGH GO UCITS ETF | Sector Equity Biotechnology
LGIM Managers (Europe) Limited · UK
AUM:$0
#– of – in Sector Equity Biotechnology ETFs
ℹ️
Reward Rating
37
Weak
34.06% 1Y return
ℹ️
Risk Rating
41
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data, holdings and expense metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Market Performance

📈 Up 34.1% over the past year, reflecting strong price momentum.

Cost Efficiency

Ongoing charge of 0.49% — moderate cost. Consider how fees compound over long holding periods.

What is BIOT?

L&G PHARMA BREAKTHROUGH GO UCITS ETF tracks Morningstar Gbl Biotechnology NR USD, providing diversified exposure across 36 holdings. Its ongoing charge is 0.49%.

Performance Highlights

Investment Breakdown

Strong Recent Performance
BIOT delivered 34.1% over the past year. Historical returns only — past performance is not indicative of future results.
Moderate Cost
Ongoing charge of 0.49%. Consider how fees compound over a long holding period.
Moderate Concentration
Top 10 holdings make up 31.7% of the ETF — a moderate level of name concentration.

Openbook Analysis

Performance: Weak (37)

The scoring profile reflects subdued historical performance over the measured period. The ongoing charge of 0.49% should be considered against long-term return expectations. Risk indicators are moderate, in line with typical market exposure (historical).

For informational and educational purposes only. Not financial advice. Past performance is not indicative of future results.

ETF Information
AUM$0
Ongoing Charge0.49%
Dividend Yield0.00%
Holdings36
Inception DateJan 2018
Domicile–
Distribution–
IndexMorningstar Gbl Biotechnology NR USD
ProviderLGIM Managers (Europe) Limited
Beta0.62
CategorySector Equity Biotechnology
CurrencyUSD
Portfolio Impact

How would BIOT affect your portfolio?

Sign in to see exactly what adding this ETF changes — sector exposure, yield, diversification, volatility. Real numbers from your actual holdings.

Sign in
Example preview
6168
+7 points · better diversified
Alternatives
Similar ETFs to compare
CSP1
iShares Core S&P 500
TER 0.07%
1Y+18.1%
AUM£78B
Yield1.3%
VUAG
Vanguard S&P 500 Acc
TER 0.07%
1Y+18.0%
AUM£12B
Yield—
SWDA
iShares MSCI World
TER 0.20%
1Y+15.4%
AUM£62B
Yield1.6%
VWRP
Vanguard FTSE All-World
TER 0.22%
1Y+14.8%
AUM£14B
Yield1.8%

Chart Tools

My Portfolio

Sign in to overlay your portfolio on the chart.

Sign in
Compare Equity
Uses ISF.L (iShares FTSE 100 ETF)
Indicators

Performance Metrics

Historical returns

6M
-0.8%
1Y
+30.4%
3Y
+24.4%
5Y
+9.3%
OpenBook InsightIf you had invested £10,000 in BIOT 5 years ago, it would have grown to £10,927 — a gain of £927.

Annual Returns

Calendar year performance

BIOT delivered positive returns in 2 of the last 5 calendar years.
YearBIOT
2026 YTD+0.9%
2025+35.8%
2024-5.3%
2023-10.2%
2022-7.5%
CAGR 4yr+1.7%
2/5 positive yearsAvg return: +2.7%Worst year: -10.2% (2023)

Technical Analysis Summary

Automated insights from historical price action and indicators

Technical Regime: MIXED
Trend Strength
100%
Positive
Volatility
19.3%
Low
Momentum
-3.0%
30-day change
Support Level
13.29
Key floor
Key Insights
  • Price is currently trading above all key moving averages.
  • Price is consolidating, with low momentum over the recent period.
  • Monitor key support and resistance levels as part of broader risk assessment.

Reward Rating Breakdown

Our reward rating analyses BIOT's attractiveness using 4 weighted factors. Each factor is scored 0-100, then combined using the weights shown below. Past performance does not guarantee future results.

Overall Reward Rating
37
Weak REWARD
Data Coverage: %
Factor Framework
Performance
Has the ETF delivered strong historical returns versus similar ETFs?
Cost Efficiency
Is the ETF cheap to own over long periods?
Income
Does it provide attractive and consistent distributions?
Diversification Quality
Does it spread exposure across holdings, sectors, and regions?

📈 Performance

Weight: 30%
53/100

Has the ETF delivered strong historical returns versus similar ETFs? Combines 1/3/5/10-year returns with the Sharpe ratio (risk-adjusted return).

1Y Return
34.06%
Very Good
3Y Return
6.39%
Neutral
5Y Return
1.60%
Weak
10Y Return
—
No Data
Sharpe Ratio
—
No Data

Moderate performance profile: 1-year return of 34.06%, 3-year annualised 6.39%, 5-year annualised 1.60%. Past performance is not indicative of future results.

💰 Cost Efficiency

Weight: 30%
30/100

Is the ETF cheap to own over long periods? Low ongoing charges compound into meaningful additional returns over a 10-year horizon.

Ongoing Charge
0.49%
Weak
Net Expense Ratio
—
No Data
Annual Turnover
—
No Data
Tracking Difference
—
No Data

Higher-than-average cost profile: ongoing charge of 0.49%.

💵 Income

Weight: 15%
15/100

Does the ETF provide attractive and consistent distributions? Combines the current yield with distribution frequency.

Distribution Yield
0.00%
Very Weak
Distribution Frequency
—
No Data

Low-income profile — better suited as a growth holding: distribution yield of 0.00%.

🌐 Diversification Quality

Weight: 25%
40/100

Does the ETF spread exposure across many holdings, sectors, and regions? Concentrated funds can be doing exactly what they're meant to do — treat the score as context, not a verdict.

Holdings
36
Very Weak
Top 10 Concentration
31.75%
Neutral
Top Sector
Healthcare96.9%
Very Weak
Top Region
North America66.9%
Neutral

Concentrated but typical for its category: 36 holdings, top 10 at 31.7%, Healthcare sector at 96.9%, North America at 66.9%.

Scores are derived from fund-provider disclosures and historical data. For informational and educational purposes only — not investment advice. Past performance is not indicative of future results.

Risk Rating Breakdown

Our risk rating analyses BIOT using 4 weighted factors. A higher score indicates higher risk. This is a framework for understanding exposure — concentrated funds can still be doing exactly what they're meant to do.

Overall Risk Rating
41
Moderate RISK
Data Coverage: 83%
Factor Framework
Holdings Concentration
How much of the fund sits in its largest positions? Few dominant names mean returns ride on those companies.
Market Exposure
Geographic, sector and cyclical dependencies. High single-country or single-sector weight increases macro sensitivity.
Volatility
Historical price movement, beta and drawdowns — how sharply the fund moves relative to the market.
Income Reliability
How dependable the distribution yield is — cyclical-sector dependency and unusually high yields can flag payout risk.

🎯 Holdings Concentration

Weight: 25%
38/100

How much of the fund sits in a small number of positions? If the top holdings dominate, returns will be driven by those specific companies rather than the broader index.

Top 10 Weight
31.75%
Lower Risk
Largest Holding
3.92%
Lower Risk
Number of Holdings
36
Elevated
HHI (weight²)
102
Low Risk

Reasonable spread across positions: top 10 holdings at 31.7%, largest single position at 3.92%, 36 total holdings.

🌍 Market Exposure

Weight: 25%
61/100

How dependent is the fund on a single country, sector or economic cycle? Heavy exposure to one market means a single macro event can drive most of the return.

Top Region
North America66.9%
Moderate
Top Sector
Healthcare96.9%
High Risk
Top 2 Sectors
100.00%
High Risk
Cyclical Sectors
3.11%
Low Risk

Notable regional or sector dependency: North America at 66.9%, Healthcare sector at 96.9%, 3.1% in cyclical sectors.

📊 Volatility

Weight: 35%
28/100

How sharply does the fund move day-to-day and how deep have its drawdowns been? High volatility means wider return outcomes over short horizons.

1Y Volatility
11.54%
Lower Risk
Beta
0.62
Lower Risk
Max Drawdown
—
No Data

Below-average volatility: 1Y volatility of 11.54%, beta of 0.62 (historical).

💵 Income Reliability

Weight: 15%
Not applicable

This is an accumulating ETF. Distributions are reinvested inside the fund, so there's no dividend-reliability risk to assess. The 15% income weight is redistributed to the other three factors.

Scores are derived from fund-provider disclosures and historical data. For informational and educational purposes only — not investment advice. Risk scoring is model-based and past data does not guarantee future results.
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.